Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia
Status:
Completed
Trial end date:
2017-04-26
Target enrollment:
Participant gender:
Summary
Standard chemotherapy is capable of eliminating most leukemic blasts in acute myeloblastic
leukemia (AML), while leukemia-initiating cells are not sufficiently eradicated. As a
consequence, refractory disease and relapse frequently occur in AML, especially in elderly
patients. The investigators propose that the addition of temsirolimus may improve standard
AML chemotherapy. Furthermore, temsirolimus may specifically target the leukemia-initiating
cells in AML, thereby reducing the risk of leukemia relapse.
The study's main part is preceded by a open label run-in part, in which optimal temsirolimus
dose and schedule for the main part o the study will be determined.